NAS10026,990+1.35%S&P7,377+0.31%GOLD$4,075−0.94%BTC$75,838+0.12%VIX25.64−9.01%latest tape · as of 20:01 UTC
The Screen · Healthcare · Medical Instruments & Supplies
Becton Dickinson
BDX · a US exchange · USD · Market cap $54.0B · 60,000 employees
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laborat…
FAIL · Does not pass the screen
211.88 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price211.88 USD at the 6 Nov 2026 close
Our value readFair vs our fair value, as of 6 Nov 2026
Positioning political buying, disclosed 2026-09-11
Options put/call open interest 0.41, read 2026-11-07
Ethical does not pass the values gate
Price211.88 USD
Fair value225.00
Ethical score10.0/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-11-04Read Accumulation198.17+6.9% to today ✓Markup gives way to Accumulation first Accumulation read since October
2026-10-25Read Markup193.76+9.4% to today ✓Accumulation gives way to Markup first Markup read since October
2026-10-18Read Accumulation193.76+9.4% to today ✓Markup gives way to Accumulation after a 5% rise in 7 days
2026-10-11Read Markup183.83+15.3% to today ✓Distribution gives way to Markup first Markup read since August
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Becton Dickinson holds its Markup at $211.88. The statistical read favours the sellers, held for 2 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 2 days
Price at the screen
$211.88
Valuation
46.13 trailing · 14.91 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.28
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
34.67%
Below 33%
Interest-bearing debt is 34.7% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.01%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
6.57%
Below 49%
Money owed to the company is 6.6% of assets, under the 49% limit.
Pass
Revenue purity
0.17%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Becton Dickinson's business is in a permissible area, but its interest-bearing debt is about 35% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BDX's ethical verdict changes
Today BDX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly a 6% discount to our $225.00 fair value, narrow competitive moat, 5.40% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 5.8% discount to the base estimate.
Where our models see it going: fair-value estimate $225.00, with a range of $219.48 to $365.79, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medical giant fails where numbers look fine
Every time a hospital stocks syringes or a lab processes samples, Becton Dickinson sits in the background supplying the kit. The shares trade at 158 dollars against a fair value near 219, and forward earnings sit at just 11.8 times. Yet none of that moves the needle for us.
We pass because the business fails our ethical screen on debt ratio. Revenue growth runs at 5 percent, profit margins sit at 5 percent and return on equity reaches only 7 percent with a narrow moat. Analyst targets cluster around 175 dollars on a buy rating, but the ethical bar is non negotiable.
The low multiple reflects modest growth and thin returns rather than hidden value. Debt levels add further caution in a sector where steady cash flow should not require heavy leverage. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BDX trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Accumulation$209.19+5.6%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$197.88+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$197.88+0.0%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$197.88-0.2%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$198.34+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$198.34+1.6%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$195.16+0.7%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup · changed$193.76+0.0%Entry 9
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (14 analysts) rates it buy, with a mean price target of $183.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
